Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457895 | 0.95 | USP30 (0.44) | USP30MEN1ALDH1A1KMT2ANSD2 | |
| Trifluoroacetic Acid SCHEMBL19639842 | 0.91 | MEN1 (0.42) | USP30MEN1ALDH1A1KMT2ANSD2 | |
| SCHEMBL19473769 | 0.89 | NSD2 (0.52) | USP30MEN1ALDH1A1KMT2ANSD2 | |
| SCHEMBL19457848 | 0.87 | KCNJ1 (0.53) | USP30NSD2L3MBTL1KCNJ1GPR119 | |
| SCHEMBL19457708 | 0.86 | USP30 (0.45) | USP30MEN1ALDH1A1KMT2ANSD2 | |
| SCHEMBL19457710 | 0.86 | USP30 (0.50) | USP30MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL19457858 | 0.84 | KCNJ1 (0.48) | USP30MEN1ALDH1A1KMT2ANSD2 | |
| SCHEMBL20985108 | 0.80 | KCNJ1 (0.40) | USP30RETKCNJ1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL19457706 | 0.79 | L3MBTL1 (0.42) | USP30MEN1ALDH1A1KMT2ANSD2 | |
| Trifluoroacetic Acid SCHEMBL19457704 | 0.77 | CDK4 (0.39) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231802-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3231802-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-10-15 | — | — | US | disclosed |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-10-15 | — | — | US | disclosed |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-07-30 | — | — | US | disclosed |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| EP-3231802-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2017-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | CASK, PDXK, NADK | USP30 3736/4885MEN1 1604/4885ALDH1A1 2209/4885 |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | CPS1, PDXK, SDHA | USP30 2195/4885MEN1 1352/4885ALDH1A1 432/4885 |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | CPS1, PDXK, SDHA | USP30 2195/4885MEN1 1352/4885ALDH1A1 432/4885 |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | USP30 3131/4885MEN1 1404/4885ALDH1A1 3033/4885 |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | KCNK2, KCNJ2, KCNK5 | USP30 3131/4885MEN1 1404/4885ALDH1A1 3033/4885 |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | CASK, PDXK, NADK | USP30 3736/4885MEN1 1604/4885ALDH1A1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.